PPL Corporation (PPL) continued its upward trend with the stock climbing 0.68% or $0.24 to close the day at $35.72 on lower than average trading volume of 2.69M shares, compared to its three month average trading volume of 3.57M. The Allentown Pennsylvania 18101 based company has been outperforming the electric utilities companies by 8.6466% for last three months and its recent gains have pushed the stock slightly up 4.9% YTD, versus the electric utilities industry which is up 2.34% for the same period. The RSI of 63.05 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
PPL Corporation, a utility company, delivers electricity and natural gas in the United States and the United Kingdom. It serves 322,000 natural gas and 403,000 electric customers in Louisville and adjacent areas in Kentucky; 543,000 customers in central, southeastern, and western Kentucky; and approximately 28,000 customers in 5 counties in southwestern Virginia, and fewer than 10 customers in Tennessee. The company also provides electric delivery services to approximately 1.4 million customers in Pennsylvania; and operates 4 electricity distribution networks in the United Kingdom, as well as delivers natural gas to customers in Kentucky; generates electricity from power plants in Kentucky; and sells wholesale electricity to 11 municipalities in Kentucky. In addition, it provides finance for the operations of PPL and subsidiaries. PPL Corporation was founded in 1920 and is headquartered in Allentown, Pennsylvania.
Carnival Corporation (CCL) had a light trading with around 2.67M shares changing hands compared to its three month average trading volume of 3.32M. The stock traded between $55.7 and $56.46 before closing at the price of $56.03 with -0.8% change on the day. The Miami Florida 33178 based company is currently trading 32.35% above its 52 week low of $42.84 and -3.05% below its 52 week high of $57.79. Both the RSI indicator and target price of 60.91 and $57.36 respectively, lead us to believe that it should be put on hold over the coming weeks.
Carnival Corporation operates as a leisure travel and cruise company in North America, Europe, Australia, and Asia. It offers cruises under the Carnival Cruise Line, Princess Cruises, Holland America Line, and Seabourn brands in North America; and Costa, AIDA, P&O Cruises (UK), Cunard, and P&O Cruises (Australia) brands in Europe, Australia, and Asia. The company operates approximately 100 cruise ships. It also owns Holland America Princess Alaska Tours, a tour company in Alaska and the Canadian Yukon, which owns and operates hotels, lodges, glass-domed railcars, and motor coaches. In addition, the company is involved in the leasing of cruise ships. It sells its cruises primarily through travel agents and tour operators. The company was incorporated in 1972 and is headquartered in Miami, Florida. Carnival Corporation is a subsidiary of Carnival Corporation & Plc.
Amgen Inc. (AMGN) traded within a range of $170.3 to $172.17 after opening the day at $171.56. The company has seen its stock increase in value by 18.53% so far this year. The stock was up close to 0.19% on light volume in last trading session and closed at $172.11 per share. After the recent gain, the stock is currently holding -1.35% below its 52 week high of $176.85 and 30.55% above its 12-month low of $133.64. The shares are up by over 17.84% in the last three months, and the RSI indicator value of 76.87 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company’s other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.